Ribociclib-Letrozole Regimen Tested in Ovarian, Endometrial Cancer
Researchers examined the results of ribociclib and letrozole as a treatment for patients with estrogen receptor-positive ovarian cancer and endometrial cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 23, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Many of the deadliest cancers receive the least amount of research funding
(Northwestern University) Many of the deadliest or most common cancers get the least amount of nonprofit research funding, reports a new Northwestern Medicine study. 'Embarrassing' or stigmatized cancers, like lung and liver, are underfunded. Colon, endometrial, liver and bile duct, cervical, ovarian, pancreatic and lung cancers were all poorly funded compared to how common they are and how many deaths they cause, the study found. In contrast, breast cancer, leukemia, lymphoma and pediatric cancers were all well-funded, respective to their impact on society. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 18, 2019 Category: Cancer & Oncology Source Type: news
Endometrial Safety of Vaginal Estrogens in Menopausal Women Endometrial Safety of Vaginal Estrogens in Menopausal Women
Does treatment of vulvar and vaginal atrophy with unopposed vaginal estrogens increase the risk for endometrial hyperplasia or cancer in menopausal women?Menopause (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 16, 2019 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news
Endometrial cancer clinical trial aims to pave the way for practice-changing therapy
(University of Colorado Anschutz Medical Campus) The University of Colorado Cancer Center is leading the way in the development of a new endometrial cancer clinical trial that may lead to practice-changing therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2019 Category: International Medicine & Public Health Source Type: news
The Case for Tumor and Germline Testing in Endometrial Cancer Patients
A new study reinforces the need for universal mismatch repair protein immunohistochemistry screening of tumors from endometrial cancer patients, as well as germline genetic testing in accordance with guidelines. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Breaking New Ground in the Treatment of Advanced Endometrial Cancer
Dr. Makker summarizes the standard of care for the treatment of advanced endometrial cancer, with a look forward to the multitude of clinical trials evaluating novel therapy combinations that are currently enrolling patients or underway. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2019 Category: Cancer & Oncology Authors: Vicky Makker, MD Source Type: news
Molecular analysis could improve the early detection and prevention of endometrial cancer
(IDIBELL-Bellvitge Biomedical Research Institute) Researchers from IDIBELL and ICO lead the proposal to evaluate genomic analyzes in cervical cytologies to improve the detection of cancer of the uterine cavity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 17, 2019 Category: Cancer & Oncology Source Type: news
Carboplatin & paclitaxel chemotherapy alone should remain standard treatment for endometrial cancer
(NRG Oncology) The New England Journal of Medicine recently published the primary endpoint of the NRG Oncology clinical trial NRG-GOG 0258, which showed that carboplatin and paclitaxel chemotherapy preceded by radiotherapy with concurrent cisplatin, or combined modality therapy, did not significantly increase recurrence-free survival for women with stage 3-4A endometrial cancer when compared to chemotherapy with carboplatin and paclitaxel alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 13, 2019 Category: International Medicine & Public Health Source Type: news
Chemo Alone in Advanced Endometrial Cancer? Chemo Alone in Advanced Endometrial Cancer?
Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with advanced endometrial carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 12, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Chemoradiation Does Not Up Survival in Endometrial Cancer
WEDNESDAY, June 12, 2019 -- For patients with stage III or IVA endometrial cancer, chemotherapy plus radiation is not associated with improved relapse-free survival versus chemotherapy alone, according to a study published in the June 13 issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 12, 2019 Category: Pharmaceuticals Source Type: news
Radiation plus chemotherapy doesn't improve endometrial cancer recurrence-free survival
(Northwestern University) The standard of care for women with stage III/IVA endometrial cancer following surgery has been chemotherapy and radiation to prevent recurrence. But in a surprising new finding, radiation combined with chemotherapy did not increase recurrence-free survival in these women, reports a National Cancer Institute-sponsored study. Chemotherapy alone should now be the standard of care for stage III uterine cancer, the lead author said. This is the first study comparing the combined regimen to chemotherapy alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 12, 2019 Category: Cancer & Oncology Source Type: news
Dr. Yoland Catherine Antill on Results of the PHAEDRA Trial
Cancer Network spoke with Yoland Catherine Antill, MD, of Cabrini Health, about the phase II PHAEDRA trial, which tested the activity of durvalumab in advanced endometrial cancer according to mismatch repair status. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Yoland Catherine Antill, MD Source Type: news
Cochrane January-March 2019: highlights from Q1
' Cochrane exists so that healthcare decisions get better. ’ That is the first sentence of our Strategy to 2020 that aims to put Cochrane evidence at the heart of health decision-making all over the world. Here ’s a look back at some key highlights of our work in the first quarter of 2019, from January to March.Cochrane began preparations for its annual flagship event,Cochrane ’s Colloquium in Santiago, Chile 22-25 October, 2019. During this time, many Cochrane contributors submitted abstracts as part of the scientific programme, this year ‘embracing diversity’. We also opened the call for hosts for the second ...
Source: Cochrane News and Events - May 7, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news
Study reveals amyloid clumps of a truncated p53 structure related to endometrial cancer
(Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)) Brazilian scientists have discovered that a truncated variant of the tumor suppressor protein p53 is present as amyloid aggregates in endometrial cancer cells. Published in the Journal of Biological Chemistry, the study points to new perspectives for treating tumors in which p53 variants are important components of these clusters, given that alterations in the p53 protein are associated with more aggressive versions of these tumors, with a high mortality rate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2019 Category: Cancer & Oncology Source Type: news
Loss of a DNA repair system creates a unique vulnerability in many cancer types
(Broad Institute of MIT and Harvard) Cancer cells adapt to potentially fatal mutations and other molecular malfunctions by adjusting one or more other genes' activity, in the process becoming dependent on those genes for their survival and growth. The resulting genetic dependencies may provide targets for developing new precision-guided drugs or other cancer treatment strategies.Reporting in Nature, researchers describe one such vulnerability shared by a large subset of colon, gastric, endometrial, and ovarian cancer cell lines. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2019 Category: Cancer & Oncology Source Type: news
